T-DXd Meaningfully Improves PFS Vs Chemo in HR+, HER2-Low Breast Cancer
Findings from the phase 3 DESTINY-Breast06 trial will be presented at a future medical meeting and shared with regulatory authorities.
Findings from the phase 3 DESTINY-Breast06 trial will be presented at a future medical meeting and shared with regulatory authorities.
Learn more about a 56-year-old woman diagnosed with well-differentiated papillary mesothelioma, and how she was diagnosed and properly treated.
Enhancing DEI in Clinical Research: Strategies Used by Clinical Investigators
Genome-driven precision oncology has revolutionized cancer treatment and opened doors to tissue-agnostic precision medicine. Kummar et al.’s study confirms the effectiveness of neurotrophic receptor …
Here, we summarize results from a phase II trial assessing the safety and efficacy of acalabrutinib in combination with lenalidomide and rituximab in patients with…
NICE recommends Oncotype DX to guide chemotherapy decisions in early-stage, HR-positive, HER2-negative breast cancer involving up to 3 positive nodes.
Although the sample size for this trial was small, data still highlight a potential benefit with nivolumab in dMMR uterine and ovarian cancers.
Two studies provide new insights on the effects of vaginal oestrogen therapy and physical exercise to tackle sexual impairment
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the…
SNB-101 has received FDA fast track designation for potential use in patients with small cell lung cancer.
Following positive response data from the phase II TRANSCEND FL study, lisocabtagene maraleucel receives accelerated U.S. FDA approval for the treatment of adult patients with…